What is VIRTUE Diagnostics?
Founded in 2019, VIRTUE Diagnostics is an innovative IVD company dedicated to developing clinical solutions for patients across all disease stages. Leveraging diverse technology platforms, the company aims to provide diagnostic tools for early screening, initial diagnosis, treatment monitoring, and minimal residual disease management. Its focus spans infectious diseases, cancer, and chronic diseases, positioning it as a key player in advancing diagnostic capabilities within these critical health sectors.
How much funding has VIRTUE Diagnostics raised?
VIRTUE Diagnostics has raised a total of $130M across 2 funding rounds:
Series A
$30M
Series B
$100M
Series A (2020): $30M with participation from Lily Asia Ventures
Series B (2022): $100M, investors not publicly disclosed
Key Investors in VIRTUE Diagnostics
Lily Asia Ventures
Lily Asia Ventures is an investment firm that has participated in VIRTUE Diagnostics' Series A funding round. Further details on their specific investment focus are not publicly available.
What's next for VIRTUE Diagnostics?
The substantial capital infusion, particularly the recent strategic investment, signals VIRTUE Diagnostics' readiness for accelerated growth and market expansion. This financing is expected to fuel further research and development, enhance manufacturing capabilities, and broaden the company's commercial reach. The company's trajectory suggests a move towards scaling its operations and solidifying its position as a leader in the IVD market, particularly in its focus areas of oncology and infectious disease diagnostics.
See full VIRTUE Diagnostics company page
